Epstein-Barr Virus Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Epstein-Barr virus (EBV) is a double-stranded DNA virus within the herpesvirus family that primarily infects B lymphocytes. Transmission of EBV occurs through various means, including deep kissing, sharing food, stem cell and organ transplantation, and blood transfusion. Following initial infection, elevated levels of viral DNA are present in salivary secretions. Children can contract the virus by consuming food pre-chewed by an infected individual. The symptomatic presentation of EBV infection includes fatigue, fever, inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver, and rash. Primary infection targets the epithelial cells of the oropharynx and parotid gland, with viral shedding continuing for weeks to months post-infection. After replicating in epithelial cells, EBV infects B cells and rapidly establishes latency. Latent EBV is implicated in the etiology of nasopharyngeal carcinoma, Burkitt's lymphoma, and other lymphoproliferative disorders, particularly in immunocompromised individuals. Diagnosis of EBV infection is most effectively achieved through serological testing, with differential diagnosis including bacterial pharyngitis (characterized by sore throat, cervical lymphadenopathy, pharyngeal swelling, and tonsillar exudates), viral pharyngitis (often presenting with fatigue, fever, rhinorrhea, or conjunctivitis), and Cytomegalovirus (CMV) infection. CMV, another member of the Herpesviridae family, presents similarly to EBV with symptoms such as sore throat, fevers, chills, elevated liver function tests, and fatigue. However, splenomegaly and lymphadenopathy are less common. Acute HIV infection is also considered in the differential diagnosis. Currently, there are no regulatory agency-approved treatments for EBV-related diseases. However, several antiviral agents have shown efficacy in inhibiting EBV replication in cell culture, including acyclovir, ganciclovir, maribavir, desciclovir, interferon-alfa, interferon-gamma, adenine arabinoside, and phosphonoacetic acid. Infectious mononucleosis, caused by EBV, is typically a self-limiting disease with a favorable prognosis, as most patients recover over time. Nevertheless, EBV infection can lead to complications, the frequency of which varies among individuals.
Thelansis’s “Epstein-Barr Virus Infection Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epstein-Barr Virus Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Epstein-Barr Virus Infection across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Epstein-Barr Virus Infection Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment